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Voltage gated potassium channel
Cardiac voltage gated potassium
channel—KvLQT1
Peptide–membrane interaction
Assembly of synthetic S5
Pore forming activity of S5 peptide in
phospholipid vesicleMutations in various voltage gated cardiac ion channels are the cause of different forms of long QT syndrome
(LQTS), which is an inherited arrhythmic disorder marked as a prolonged QT interval on electrocardiogram.
Of these LQTS1 is associated with mutations in the gene encoding KCNQ1 (KvLQT1) channel. One responsible
mutation, G269S, in the S5 segment of KvLQT1, that affects the proper expression and function of channel
protein leads to LQTS1. Our objective was to study how G269S mutation interferes with the structure and
function of a synthetic S5 segment of KvLQT1 channel. One wild type 22-residue peptide and another mutant
peptide of the same length with G269S mutation, derived from the S5 segment were synthesized and labeled
with ﬂuorescent probes. The mutant peptide exhibited lower afﬁnity towards phospholipid vesicles as
compared to the wild type peptide and showed impaired assembly and localization onto the lipid vesicles as
evidenced by membrane-binding, energy transfer and proteolytic cleavage experiments. Loss in the helical
content of S5 mutant peptide in membrane-mimetic environments was observed. Furthermore, it was
observed that G269S mutation signiﬁcantly inhibited the ability of S5 peptide to permeabilize the lipid
vesicles. The present studies show the basis of change in function of the selected S5 segment as a result of
G269S mutation which is associated with LQT1 syndrome. We speculate that the structural and functional
changes related to the glycine to serine amino acid substitution in the S5 segment may also inﬂuence the
activity of the whole KvLQT1 channel.9-ﬂuorenyl)methoxycarbonyl;
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Voltage gated potassium channels (Kv) regulate the membrane
potential of many excitable tissues. Kv channels are typically closed at
the resting membrane potential, and open upon cell membrane
depolarization. Kv channels bring about neuronal signaling, cardio-
vascular function, immune cell activation, muscle contraction and
many other physiological processes [1–3]. Lack of proper expression
and function of these channels cause severe disorders in humans such
as episodic ataxia, long QT syndrome and epilepsy. The malfunction in
Kv channels arises due to the mutations in the genes encoding that
particular channel [4].Long QT syndrome 1 (LQTS1), results from mutations in the gene
encoding the KCNQ1 (KvLQT1) channel of the heart. These mutations
lead to structural abnormalities in the KvLQT1 channels which cause
sustained inward current or reduced outward current that prolongs
the action potential and thus results in long QT interval which leads to
LQT1 syndrome [5–8]. In cardiac myocytes, KvLQT1 tetramers
combine with two KCNE1 (MinK) β-subunits to form functional Kv
channel. These channels underlie IKS, a slow delayed rectiﬁer K+
current that is involved in repolarization of the cardiac action
potential and an important determinant of the QT interval of the
electrocardiogram. Mutations that alter the function of either KvLQT1
or MinK subunit results in long QT1 syndrome [8–11].
To date, nearly 100 different KvLQT1 mutations have been
reported as responsible for the cardiac long QT1 syndrome, charac-
terized by prolonged QT interval, and sudden death [12]. It has been
reported that a LQT1 syndrome is associated with the substitution of
glycine to serine at position 269 of S5 segment. G269S mutation alters
the structural and functional property of KvLQT1 channel subunits
resulting in long QT1 syndrome which can lead to arrhythmias, ven-
tricular ﬁbrillation and cardiac arrest [13–18]. Interaction of these
channel proteins with membranes and assembly there in are
important issues related to their functions. However, the way the
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protein is unknown. This work has been aimed to study the structural
and functional changes associated with the LQT1 syndrome-causing
mutation in some conserved segments of KvLQT1 channel. To look
into the structural and functional alteration involved with the G269S
point mutation in the concerned segment, a 22-residue peptide from
S5 segment of KvLQT1was synthesized; besides themutant peptide of
the same size with glycine to serine substitution at position 269,
which causes the LQT syndromewas synthesized. The effect of glycine
to serine substitution, on the secondary structure, assembly and
membrane permeability of 22-residue segment was studied in detail.
2. Materials and methods
2.1. Materials
Rink amide MBHA resin (loading capacity: 0.4–0.8 mmol/g) and
all the N-α Fmoc and necessary side-chain protected amino acids
were purchased from Novabiochem, Laufelﬁngen, Switzerland. Cou-
pling reagents for peptide synthesis like 1-hydroxybenzotriazole
(HOBT), di-isopropylcarbodiimide (DIC), 1,1,3,3-tetramethyluronium
tetraﬂuoroborate (TBTU) and N, N′-diisopropylethylamine (DIPEA)
were purchased from St. Louis, MO, Sigma, USA. Dichloromethane
(DCM), N, N′ dimethylformamide (DMF) and piperidine were of
standard grades and procured from reputed local companies.
Acetonitrile (HPLC grade) was procured from Merck, Mumbai India
while triﬂuoroacetic acid (TFA), triﬂuoroethanol (TFE) and sodium
dodecyl sulfate (SDS) were purchased from Sigma. Egg phosphatidyl-
choline (PC) and egg phosphatidylglycerol (PG) were obtained from
Northern Lipids Inc., Burnaby BC V5J5J1 Canada. 3,3′-dipropylthiadi-
carbocyanine iodide (diS-C3-5), NBD-ﬂuoride (4-ﬂuoro-7-nitrobenz-
2-oxa-1, 3-diazole) and tetramethylrhodamine succinimidyl ester
were procured fromMolecular probes, Eugene, OR. The other reagents
employed in this study were of analytical grade and procured locally;
buffers were prepared in milli Q water (USFELGA).
2.2. Peptide synthesis, ﬂuorescent labeling and puriﬁcation
The peptide was synthesized manually on solid phase. Stepwise
solid phase synthesis was carried out on rink amide MBHA resin
(0.15mmol) utilizing the standard Fmoc chemistry, employing DIC/
HOBT or TBTU/HOBT/DIPEA coupling procedure [19,20]. De-protec-
tion of α-amino group and the coupling of amino acids were checked
by Kaiser test [21] for primary amines. After the synthesis was over,
each peptide was cleaved from the resin with simultaneous de-
protection of side chains by treatment with a mixture of TFA/phenol/
thioanisole/1,2-ethanedithiol/water (82.5:5:5:2.5:5 v/v) for 6–7h.
Labeling at the N-terminus of a peptide was achieved by a standard
procedure reported earlier [22,23]. In brief, 15–20 mg of resin-bound
peptidewas treatedwith 25% piperidine (in DMF) to remove the Fmoc
group from the N-terminal amino group. The resin was washed and
dried. Then Fmoc de-protected resin-bound peptides were incubated
with tetramethylrhodamine succinimidyl ester (2–3 equiv.) in
dimethylformamide in the presence of 5% diisopropylethylamine for
48–72 h, which ultimately resulted in the formation of Nα–Rho-
peptides. Similarly, resin-bound peptides were treated with NBD-
ﬂuoride (2–3 equiv.) to obtain Nα–NBD-peptides. After sufﬁcient
labeling, the resins were washed with DMF and DCM in order to
remove the un-reacted probe. The peptides were cleaved from the
resin as above and precipitated with dry ether. All the peptides were
puriﬁed by RP-HPLC on an analytical Vydac C4 column using a linear
gradient of 0–80% acetonitrile in 45 minwith aﬂow rate of 0.6 ml/min.
Both acetonitrile andwater contained 0.05% TFA. The puriﬁed peptides
were ∼90% homogeneous as shown by HPLC. Each peptide was
subjected to ES-MS analysis for the detection of molecular mass.2.3. Preparation of large unilamellar vesicles (LUVs)
LUVs were prepared by a standard procedure [24,25] as follows.
Dry lipids containing PC/PG (1:1 w/w) of required amounts were
dissolved in CHCl3/MeOH (2:1 v/v) in a small glass vial. Solventswere
evaporated under a stream of nitrogen, which resulted in the
formation of a thin ﬁlm on the wall of the glass vessel. Also, ﬁlms
were dried overnight under vacuum to remove traces of solvents. The
thin ﬁlm was re-suspended in buffer at a concentration of 8.2 mg/ml
by vortex mixing. The lipid dispersions were then sonicated in a bath-
type sonicator (Laboratory Supplies Company, New York) for 10–
20 min until it became transparent. The lipid concentration was
determined by phosphorus estimation [26].
2.4. Circular dichroism (CD) experiments
The CD spectra of peptides were recorded in phosphate buffered
saline (PBS, pH 7.4), 40% TFE and 1% SDS by utilizing a Jasco J-710
spectropolarimeter, Easton, MD, averaged over three scans, and
baseline-corrected. Noise reduction was performed by using the
manufacturer's software. The spectropolarimeter was calibrated
routinely with 10-camphor sulphonic acid. The samples were scanned
at room temperature (∼30 °C) with the help of a capped quartz
cuvette of 0.2 cm path length in thewavelength range of 250–195 nm.
An average of 4–6 scans was taken for each sample with a scan speed
of 20 nm/min and data interval of 0.5 nm for peptide concentration of





where [θ]222 was the experimentally observed mean residue
ellipticity at 222 nm. The values for [θ]222100 and [θ]2220 that correspond
to 100% and 0% helix contents were considered to have mean
residue ellipticity values of −32,000 and −2000 respectively at
222 nm [28].
2.5. Membrane-binding experiments
The afﬁnity of the peptide for phospholipid vesicles was deter-
mined by binding experiments as reported earlier [23,29–31]. In brief
small unilamellar vesicles were added gradually to a freshly dissolved
NBD-labeled peptide of ∼0.30 μM concentration at room temperature.
Fluorescence intensities of NBD-labeled peptides alone and after each
addition of lipid vesicles were recorded on a Perkin Elmer spectro-
ﬂuorimeter, model LS-50B MA, USA, with the excitation and emission
wavelengths set at 467 and 528 nm respectively. The excitation and
emission slits were ﬁxed at 8 and 6 nm respectively. The contributions
of lipid to any of the recorded signal were measured by titrating the
unlabeled peptide (at the concentration of NBD-labeled peptide) with
the same amount of lipid vesicles and were subtracted from the





where Xb* is deﬁned as the molar ratio of bound peptide per 60% of the
total lipid, assuming that the peptides were initially partitioned only
over the outer leaﬂet of the LUVs as suggested by Beschiaschvili and
Seelig [32]. Kp* represents the partition coefﬁcient and Cf indicates the
concentration of the free peptide at equilibrium.
Xb can be calculated by extrapolating the ﬂuorescence signal
Finﬁnity (ﬂuorescence signal when all the peptide molecules are bound
to lipid) from a double-reciprocal plot of F (peptide ﬂuorescence in
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bound (fb) was determined by the following equation.
fb = ðF−F0Þ= ðFinfinity−F0Þ
where F is the ﬂuorescence of the peptide when it is bound to lipid
and F0 is the ﬂuorescence of the peptide in its unbound state. When fb
is known, Cf can easily be calculated for each concentration of the
lipid. Kp* can easily be determined from the slope of the plot of Xb* and
Cf. Partition coefﬁcient of each of the peptides was determined as the
average of the values obtained from two-three independent experi-
ments as described previously [33,34].
2.6. Enzymatic cleavage experiments
In order to detect the location of the NBD-labeled peptide in its
membrane-bound state, enzymatic cleavage experiments were
performed as reported earlier [23,35]. In brief, PC/PG lipid vesicles
were ﬁrst added to the NBD-labeled peptide. When major portion of
the peptide was bound to the lipid vesicles as detected by the
saturation of the ﬂuorescence level, proteinase-k (ﬁnal concentration,
10.0 μg/ml) was added. In this experiment ﬂuorescence of NBD-
labeled peptide was recorded at 528 nm with respect to time (in sec)
with excitation wavelength set at 467 nm. In the control experiment
proteinase-k was ﬁrst added to NBD-labeled peptide and then lipid
vesicles were added. Percentage of a NBD-labeled peptide protected
(Pp) from proteinase-k cleavage in its membrane-bound state was
determined by the following equation:
Pp = fðFf−FcÞ= ðFm−FcÞg × 100%
where Ff=Final ﬂuorescence of the NBD-labeled peptide after protein-
ase-k treatment in itsmembrane-bound state; Fc=Controlﬂuorescence
of proteinase-k-treated NBD-labeled peptide in PBS after addition of
lipid vesicles; and Fm=Maximum ﬂuorescence of the membrane-
bound NBD-labeled peptide before proteinase-k treatment.
2.7. Fluorescence resonance energy transfer experiment
Fluorescence energy transfer experiments were performed with
excitation wavelength set at 467 nm and emission range of 500 to
600 nm. 0.3 µM of the NBD-labeled peptide was taken in a ﬂuorimeter
cuvette. 780 µM of the phospholipid vesicles was added to the NBD-
labeled peptide to ensure that the peptides were bound to the
membrane. Now Rho-labeled acceptor peptide was added to the
donor peptide–lipid complex. Energy transfer from donor to acceptor
was determined by subtracting the acceptor ﬂuorescence in the
presence of lipid and unlabeled donor from the ﬂuorescence signal
obtained in the presence of donor, acceptor and lipid vesicles.
The efﬁciency of energy transfer (E) was determined by the
decrease in donor's ﬂuorescence in the presence of the acceptor as
reported earlier [23,36]. The percentage of energy transfer was
calculated by the following equation.
E = fðID0−IDAÞ= ID0g × 100
where ID0 and IDA are the ﬂuorescence intensities of the NBD-labeled
donor peptide in the absence and presence of the Rho-labeled
acceptor peptide respectively at the emission maxima of the donor
after correcting the light scattering of the lipid vesicles and emission
of the acceptor.
2.8. Calcein release from the calcein-entrapped lipid vesicles
Peptide-induced release of calcein from calcein-entrapped lipid
vesicles was employed to detect the permeabilization of phospholipidmembrane in the presence of S5 peptide and its mutant. Calcein-
entrapped lipid vesicles were prepared with a self-quenching
concentration (60 mM) of the dye in 10 mM HEPES at pH 7.4 as
reported earlier [37,38]. Brieﬂy, thin ﬁlm of lipid (PC/PG) was re-
suspended in calcein solution, vortexed for 1–2 min and then
sonicated in a bath-type sonicator. The non-encapsulated calcein
was removed from the liposome suspension by gel ﬁltration using a
sephadex G-50 column. Usually lipid vesicles are diluted to approx-
imately 10 fold after passing through a G-50 column. The eluted
calcein-entrapped vesicles were diluted further in the same buffer to a
ﬁnal lipid concentration of ∼3.0 μM for the experiment. Peptide-
induced release of calcein from the lipid vesicles was monitored
by the increase in ﬂuorescence due to the dilution of the dye from its
self-quenched concentration. Fluorescence was monitored at room
temperature with excitation and emission wavelengths ﬁxed at 490
and 520 nm respectively. The peptide-induced release of calcein from
the calcein-entrapped lipid vesicles was measured in terms of
percentage of ﬂuorescence recovery (Ft) as deﬁned by [22,23]
Ft = ½ðIt−I0Þ= ðIf−I0Þ × 100%
where It=the observed ﬂuorescence after the addition of a peptide at
time t, I0=the initial ﬂuorescence of calcein-entrapped vesicles and
If=the increase in ﬂuorescence observed after the addition of triton
X-100 (0.1% ﬁnal concentration) to the dye-entrapped vesicle
suspension.
3. Results
3.1. Design and synthesis of peptides derived from conserved S5 segment
of KvLQT1 potassium channel
The multiple sequence alignment of the S5 segment of KvLQT1
depicts the conservation of glycine residue at 269th position in the
homologous channel proteins of the same family (Fig. 1A). In order to
investigate the plausible effect of the disease (LQTS1) causing, G269S,
mutation in the assembly and function of the concerned S5 segment, a
22-residue wild type and the mutant peptide corresponding to the
amino acid region, 262–283 of S5 segment of KvLQT1 channel, were
designed and synthesized (Fig. 1B). Fig. 1C represents the Schiffer and
Edmundson wheel projections of the synthetic S5, which shows the
arrangement of hydrophobic and hydrophilic amino acids revealing
the amphipathic nature of the peptide and location of glycine in the
hydrophobic face of the peptide.
3.2. G269S mutation impeded the S5 peptide-induced permeability of
negatively charged PC/PG lipid vesicles
The S5 segment lines the pore of Kv channel along with S6
segment. In order to check the ability of S5 and its analogue to
permeabilize the phospholipid membrane, release of calcein from
calcein-entrapped lipid vesicles in the presence of these peptides
was measured. As shown in Panel A of Fig. 2, the synthetic S5 peptide
triggered the release of liposome-encapsulated calcein in a dose-
dependent manner from PC/PG lipid vesicles as evidenced by the
increase in calcein ﬂuorescence following the addition of peptide.
However, the S5 mutant peptide was signiﬁcantly less efﬁcient than
the wild type S5 in releasing calcein from these (Fig. 2B) lipid
vesicles indicating the abrogation of S5 peptide-induced membrane
permeability following the glycine to serine substitution in this
segment. It can be inferred that proper functioning of the selected S5
segment was averted by the disease causing G269S mutation in the
synthetic peptide S5. Moreover, as shown in Fig. 2C, the plot of
percentage of ﬂuorescence recovery, a measure of peptide-induced
membrane permeability, clearly indicated that themutant wasmuch
less active than the wild type S5 in releasing liposome-encapsulated
Fig. 2.Detection of calcein release induced by S5 and G269Smutant S5 peptide from the
PC/PG lipid vesicles entrapped with calcein by recording its ﬂuorescence. Panels A and
B show the proﬁles of calcein release induced by increasing concentrations of S5 and
Mut-S5 respectively as measured by the increase in calcein ﬂuorescence with respect to
time from calcein-entrapped PC/PG lipid vesicles (3.0 μM). Black line, gray line and
light gray line are 0.2, 0.4 and 0.7 μMpeptides of S5 in panel A and 0.3, 0.6 and 0.9 μMof
Mut-S5 in panel B. Panel C depicts the relative membrane permeability of the S5 wild
and mutant peptides in PC/PG lipid vesicles as shown by the plots of percentage of
ﬂuorescence recovery with respect to peptide to lipid molar ratio. Symbols: closed
squares, S5 and closed circles, Mut-S5.
Fig. 1. Panel A, Sequence alignment of S5 segment (amino acids, 262–283) of human
KvLQT1 with human KCNQ4, KCNQ3 and nKQT1of Caenorhabditis elegans homologous
channels. Conserved G269 is marked in bold letter. The numbers above the amino acids
indicate the corresponding amino acid numbers in the KvLQT1 protein. Panel B,
Peptides designed from the S5 segment of KvLQT1 channel used in the study. Conserved
G269 is marked in bold letter and mutated amino acid is marked as bold and
underlined. (X = H, NBD and Rho). The amino acid marked with star in panels A and B
indicates the amino acid that has beenmutated. Panel C, Schiffer and Edmundson wheel
projections of ﬁrst 18 amino acids of S5 generated by Gene Runner program.
Hydrophobic amino acids are marked as bold and shaded while hydrophilic amino
acids are in regular characters.
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cardiac cell membrane contains both zwitterionic as well as
negatively charged phospholipids [39,40]; lipid vesicles, prepared
with zwitterionic PC and negatively charged PG, were used in this
study as a negatively charged model membrane. Furthermore,
ﬂuorescent labeled S5 peptide also induced appreciable calcein
release (∼90% to its unlabeled version) from PC/PG lipid vesicles
suggesting that labeling of the peptide did not alter its activity.
3.3. G269S mutation inﬂuenced the membrane-binding property of
synthetic S5 peptide
To further examine the basis of impairment of membrane per-
meation by S5 mutant peptide in PC/PG lipid vesicles as compared
to its wild type, the interaction of both peptides to PC/PG lipid
vesicles was studied in detail. To detect the binding of S5 and its
mutant to phospholipid vesicles, the peptides were labeled by
ﬂuorescent probe NBD. The sensitivity of the NBD probe to the
dielectric constant of the medium has been exploited extensively
to detect the binding of the NBD-labeled peptide to membrane
[34,41–43].
Fluorescence emission spectra of NBD-labeled S5 and Mut-S5
were recorded in aqueous buffer and in the presence of PC/PG lipid
vesicles. The ﬂuorescence spectra of wild type and mutant peptides
exhibited broad emission maxima around 543±1 nm in phosphate
buffer indicating the location of the NBD probe, attached to the N-
terminal of the peptides in the hydrophilic environment [43]. How-
ever, in the presence of PC/PG (1:1, w/w) phospholipid vesicle
ﬂuorescence spectra of the NBD-labeled S5 and mutant peptide
exhibited a blue shift of emission maxima concomitant with
signiﬁcant increase in ﬂuorescence (Fig. 3). These shifts of emissionmaxima towards the shorter wavelength with increased ﬂuores-
cence indicated the relocation of the probe in the hydrophobic
environment due to binding of the peptides to phospholipid
vesicles. Wild type S5 exhibited an emission maximum of 527±
1 nm in the presence of PC/PG lipid vesicles, which is shorter than
the emission maximum of 533 nm, characteristic of the location of
the NBD probe on the surface of membrane [44]. This emission
maximum further suggested that the N-terminal of S5 was to some
extent inserted in the bilayer of the PC/PG lipid vesicles. However,
the NBD-labeled S5 mutant peptide displayed an emission maxi-
mum around 531–532 nm in the presence of PC/PG lipid vesicles
suggesting that its N-terminal was most likely located on the surface
of the membrane.
These results clearly demonstrated that though both wild type and
the mutant peptides derived from S5 segment of KvLQT1 channel
bound to PC/PG lipid vesicles, glycine to serine amino acid
substitution disturbed the binding property and localization of wild
type peptide onto the lipid vesicles.
Fig. 4. Determination of the afﬁnity of NBD-labeled-S5 and -G269S mutant peptide
(0.3 μM) to phospholipid vesicles as detected by titration with PC/PG lipid vesicles.
Fluorescence intensities of these labeled peptides were recorded in the absence and
presence of varying amounts of lipid vesicles in PBS as described in the Materials and
methods section. Panel A, Binding curve of S5 and Mut-S5 in PC/PG lipid vesicles. Panel
B, Binding isotherm of S5 in PC/PG lipid vesicles. Panel C, Binding isotherm of Mut-S5 in
PC/PG lipid vesicles. Symbols: In panel A, squares and circles represent S5 and Mut-S5;
in panel B squares represent S5 and in panel C squares represent Mut-S5.
Fig. 3. Detection of binding of NBD-labeled-S5 and -G269S mutant peptide to lipid
vesicles by recording ﬂuorescence of these labeled peptides in PBS in the absence and in
the presence of PC/PG vesicles. Squares and circles represent S5 and Mut-S5
respectively. Closed symbols, 0.3 μM NBD-labeled-S5 and its mutant peptide in PBS;
open symbols, NBD-labeled peptides in the presence of 780 μM PC/PG lipid vesicles.
465R. Verma, J.K. Ghosh / Biochimica et Biophysica Acta 1798 (2010) 461–4703.4. G269S mutation decreased the afﬁnity of S5 peptide towards PC/PG
lipid vesicles
The afﬁnity of S5 and its mutant to the PC/PG vesicles was
determined by the binding experiments utilizing their NBD-labeled
analogues and LUVs. Fluorescence signal of the NBD-labeled peptide
as a result of its binding to the phospholipid membrane was plotted
with respect to lipid/peptide molar ratio. Fig. 4A depicts the binding
curve for S5 and Mut-S5 peptides in PC/PG lipid vesicles. Both plots
indicate a gradual increase in ﬂuorescence with increase in lipid
concentration indicating a progressive binding of the NBD-labeled
peptide molecules to the lipid vesicles. Binding isotherms were
generated by plotting Xb* with respect to Cf as has been described in
the Materials and methods section. Partition coefﬁcients of the NBD-
labeled peptides to the phospholipid vesicles were estimated from the
slope of the binding isotherms after extrapolating to zero. NBD-
labeled S5 exhibited an appreciable afﬁnity for PC/PG lipid vesicles as
indicated (Fig. 4B) by its partition coefﬁcient of 3.8 (±0.1)×104 M−1,
very similar to that of the surface-active peptides, derived from
antimicrobial peptides, bacterial toxins and viral fusion proteins
[22,23,45,46]. The estimated partition coefﬁcient for the mutant
peptide was 0.26 (±0.1)×104 M−1 in the same kind of lipid vesicles.
The binding isotherms of NBD-labeled Mut-S5 peptide in PC/PG
(Fig. 4C) vesicles were linear in nature, suggesting that the binding of
the mutant peptide to the phospholipid vesicles was a simple
adhesion process and not associated with the formation of large
aggregates there in PC/PG lipid vesicles.
However, the binding isotherm of NBD-labeled S5 in PC/PG
vesicles (Fig. 4B) bent downward appreciably and deviated from
linearity. As suggested earlier, this kind of curve indicates the co-
operativity in binding of the peptide molecules to membrane
[22,34,45]. The data indicated that the synthetic S5 segment formed
large aggregates in lipid vesicles like pore-forming peptides, pardaxin
and alamethicin [22,45]. Furthermore, these binding isotherms
revealed that G269S mutation inhibited the wild type NBD-labeled
S5 to form large aggregates in PC/PG lipid vesicles.
3.5. G269S mutation caused an easy cleavage of NBD-labeled S5 peptide
by proteinase-k in its membrane-bound state
To further examine the effect of replacement of glycine at 269
position by serine on the localization of the peptides onto the
membrane, proteolytic cleavage experiments were performed with
NBD-labeled peptides [23,36].
The basis of this experiment is that NBD-labeled peptides, bound
onto the membrane surface, are easily cleaved by a proteolyticenzyme like proteinase-k, which can be monitored by the decrease in
NBD-ﬂuorescence from the characteristic membrane-bound level. On
the other hand, a membrane-inserted peptide will not be accessible to
proteinase-k and therefore the NBD-ﬂuorescence will not decrease.
Proﬁle ‘a’ of panel A in Fig. 5 describes the proteolytic cleavage
experiment with NBD-labeled wild type S5 in PC/PG lipid vesicles. At
time point 1 NBD-labeled S5 was added to the buffer followed by the
addition of PC/PG lipid vesicles at time point 2. The addition of lipid
vesicles resulted in an increase in NBD-ﬂuorescence due to binding of
the peptide to the lipid vesicles.
At time point 3 when NBD-ﬂuorescence has reached the plateau,
indicating a saturation of binding of the labeled peptide to the
membrane, proteinase-k was added. The addition of proteinase-k
resulted in much less decrease in NBD-ﬂuorescence level as compared
to its maximum membrane-bound level before proteinase-k treat-
ment. The percentage membrane-bound NBD-S5 peptide protected
from proteinase-k cleavage was ∼70% as per the equation depicted in
the Materials and methods section of concerned portion. The result
indicated that NBD-S5 appreciably protected itself from the digestion
by proteolytic enzyme. No further decrease in the ﬂuorescence was
Fig. 6. Determination of secondary structures of S5 and G269S mutant peptides by
recording their CD spectra in 1% SDS micelles (A) and in 40% TFE (B) in water. Symbols:
solid line, S5; dash, Mut-S5. The concentrations of S5 and Mut-S5 were 23.9 and
23.6 μM respectively.
Fig. 5. Detection of the localization of NBD-labeled-S5 peptide and its analogue in their
membrane-bound state by recording the ﬂuorescence proﬁles of these labeled peptides
with respect to time (s) in different experimental conditions. Panel A, S5 and panel B,
Mut-S5. In trace a (gray line), 780 μM PC/PG lipid vesicles were added to 0.3 μM NBD-
labeled S5 and G269S mutant peptide and then proteinase-k (10.0 μg/ml, ﬁnal
concentration) was added to membrane-bound peptide. In trace b (black line),
proteinase-k was ﬁrst added to the NBD-labeled peptides prior to the addition of lipid
vesicles. Trace b (black line) is control. 1, 2, and 3 indicate the addition of peptide, lipid
vesicles and proteinase-k respectively.
466 R. Verma, J.K. Ghosh / Biochimica et Biophysica Acta 1798 (2010) 461–470observed even after the incubation of ∼2000 s. This result indicates
that at least a part of the peptide was hidden inside the lipid bilayer
and hence not cleaved even after a long incubation. A control
experiment (proﬁle ‘b’) was performed in order to check the cleavage
of the peptide when it was not bound to phospholipid vesicles.
Proteinase-k was added to the NBD-labeled peptide, incubated for
sufﬁcient time and then lipid vesicles were added. In this case
addition of lipid vesicles resulted only in a small increase of NBD-
ﬂuorescence (compared to the previous experiment when vesicles
were added to NBD-S5 before proteinase-k treatment) indicating that
the peptideswere cleaved by the enzyme and therefore unable to bind
to the membrane.
Similar experiments were carried out with NBD-labeled S5 mutant
peptide. For example, ‘a’ in panel B depicts the experimental proﬁle of
NBD-Mut-S5. In contrast to the wild type peptide, NBD-Mut-S5 was
easily cleaved by proteinase-k in its membrane-bound state as
evident from the sharp decrease in NBD-ﬂuorescence after the
addition of proteinase-k. The corresponding control experiment
(proﬁle ‘b’ of panel B) suggested that the mutant peptide was also
cleaved easily when it was not bound to the membrane. As per the
equation employed for determination of percentage of protection for a
NBD-labeled peptide against proteinase-k cleavage in its membrane-
bound state, the NBD-labeled mutant peptide was only ∼30%
protected as compared to 70% for NBD-S5.
These results suggest that the S5 wild type and mutant peptides
were cleaved easily in aqueous buffer by proteinase-k. However, only
the S5 wild type peptide resisted the proteolytic digestion after
binding to PC/PG lipid vesicles probably due to its insertion into the
lipid bilayer. Thus the data suggested that G269S mutation decreasedthe stability of S5 peptide in PC/PG lipid vesicles leading to early
cleavage by proteinase-k.
3.6. G269S mutant S5 peptide exhibited signiﬁcantly reduced helical
structure in membrane-mimetic environments
Circular dichroism studies were employed in order to determine
the secondary structure of these peptides in aqueous and membrane-
mimetic environments [47]. Secondary structures were determined in
aqueous phosphate buffer saline (PBS), and in membrane-mimetic
environments like SDS micelles and 40% TFE in water with the help of
mean residual ellipticity values at 222 nm. Fig. 6 depicts the circular
dichroism studies on these peptides in different environments. The
two peptides exhibited mostly random coil structure in PBS, so not
presented. The estimated helical structure as per the mean residual
ellipticity value at 222 nm of the CD spectra of S5 and Mut-S5 were
53%, 5.7% in 1% SDS and 57.7%, 12% in 40% TFE in water (Table 1).
3.7. G269S mutation inhibited the self-assembly of S5 peptide in
phospholipid vesicles
Proper assembly of S5 peptide is a prerequisite for exhibiting its
pore-forming activity. In order to evaluate any possible role of this
conserved glycine at 269 position in the assembly of S5 segment in
membrane, ﬂuorescence energy transfer experiments were carried
out in the presence of phospholipid vesicles. In order to perform the
energy transfer experiments, both the wild type S5 and its mutant
were labeled by ﬂuorescence energy donor NBD and energy acceptor
rhodamine. These two probes fulﬁll the spectroscopic criteria of
ﬂuorescence resonance energy transfer when they are in close
proximity. Therefore, the assembly of a peptide can be determined
with the help of energy transfer experiment between its NBD- and
rhodamine-labeled analogues.
Panel A of Fig. 7 shows the ﬂuorescence spectra of peptide energy
transfer experiments between NBD-S5 peptide and Rho-labeled S5 in
PC/PG lipid vesicles. Fluorescence spectra of NBD-S5 in PC/PG vesicles
were recorded in the presence of increasing amounts of Rho-S5. As
Table 1
The mean residue ellipticity values of S5 and its mutant peptide at 222 nm in different
environments and corresponding percentage helicity.








S5 17,900 19,300 53.0 57.7
Mut-S5 3700 5600 5.7 12.0
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the membrane-bound donor NBD-S5 resulted in an appreciable
decrease in NBD-ﬂuorescence concomitant with the increase in
rhodamine ﬂuorescence. This observation suggested that S5 peptide
self-assembled in PC/PG lipid vesicles.Fig. 7. Self-assembly of S5 and G269S mutant peptide by studying the ﬂuorescence
energy transfer experiments with NBD-labeled donor and Rho-labeled acceptor
peptides in PC/PG lipid vesicles. The spectra were recorded with the donor peptide
alone and in the presence of varying concentrations of acceptor peptide with excitation
wavelength set at 467 nm. Panel A, the spectra of NBD-S5 (0.3 μM) in the presence of
780 μM of PC/PG (1:1) lipid vesicles alone (solid line) with various concentrations of
Rho-S5: dash, 0.21 μM; dot, 0.4 μM; short dash dot, 0.62 μM short dash dot dot, 0.85 μM.
Panel B, the spectra of NBD-Mut-S5 (0.3 μM) in the presence of 780 μM of PC/PG (1:1)
lipid vesicles alone (solid line) with various concentrations of Rho-Mut-S5: dash,
0.45 μM; dot, 0.88 μM. Panel C, the plot showing percentage experimental energy
transfers of different pairs and theoretical energy transfer corresponding to randomly
distributed donor and acceptor with respect to the molar ratio of bound acceptor and
lipid. Symbols: squares, S5; circles, Mut-S5.Panel B of Fig. 7 depicts the results of energy transfer experiments
between NBD-Mut-S5 and Rho-Mut-S5 peptide in PC/PG vesicles. In
contrast to the wild type peptide, ﬂuorescence of the donor peptide
decreased only a little as a result of the addition of the acceptor
peptide Rho-Mut-S5. These results clearly suggested that the Mut-S5
peptide did not self-assemble signiﬁcantly in PC/PG vesicles and
therefore, no appreciable decrease in ﬂuorescence of NBD-Mut-S5
was observed when Rho-Mut-S5 was added to the former's
membrane-bound state.
In order to conﬁrm that the observed energy transfer was due to
the assembly of the peptides, the percentages of energy transfer with
different pairs of energy donor and acceptor were compared with that
of the randomly distributed energy donor and acceptor as described
earlier [36,48]. Panel C of Fig. 7 shows such plots, which clearly
indicate that the energy transfer efﬁciencies of NBD-S5and Rho-S5 in
PC/PG vesicles were much above the random distribution level.
However, energy transfer efﬁciency of Mut-S5 pair was close to the
random distribution level.
4. Discussion
The data presented here indicate that the changes reported in the
functional property of KvLQT1 channel [18,49] owing to G269S
mutation can produce signiﬁcant alterations in the functional activity
of the synthetic, 22-residue, S5 peptide which is associated with its
binding, secondary structure and assembly in phospholipid membrane.
The conserved nature of glycine at position 269 in the homologous
proteins reﬂects the noteworthy importance of this residue in the
structure and/or function of the S5 segment of KvLQT1 channel protein.
The synthetic S5 segment of KvLQT1 induced the release of calcein
from calcein-entrapped PC/PG lipid vesicles much more efﬁciently
than its mutant,Mut-S5, of the same size (Fig. 2). Binding experiments
by employing the NBD-labeled peptides indicated that S5 and its
mutant peptides bound onto the PC/PG lipid vesicles (Fig. 3).
However, themutant peptidewith G269Smutation showed a reduced
afﬁnity than S5 towards the PC/PG lipid vesicles (Fig. 4), reﬂecting
that G269S mutation in S5 inﬂuenced its binding property in lipid
vesicles.
Proteolytic cleavage experiments (Fig. 5) with NBD-labeled S5
wild type and mutant peptide indicated that the wild type S5 peptide
was probably inserted into the lipid bilayer while the mutant peptide
resided on the surface of the lipid vesicles and hence was cleaved
promptly by the enzyme. These results indicated the role of conserved
glycine in localization of this synthetic S5 peptide in the PC/PG lipid
vesicles. The results of the proteolytic cleavage experiments were
supported by the characteristic emission spectra of NBD-labeled wild
type and mutant peptide in negatively charged lipid vesicles.
The observed emission maximum of around 527±1 nm exhibited
by NBD-S5 in PC/PG lipid vesicles (Fig. 3) was much shorter than
that observed for NBD probe (533 nm) located on the surface
of the membrane [44]. Whereas, emission maximum exhibited by
NBD-Mut-S5 in PC/PG lipid vesicles (531–532 nm) was close to
the characteristic emission maximum of the probe, located onto the
membrane surface. Earlier reports also indicated that various disease
causing mutations due to amino acid substitution by polar residues
caused a transverse shift in the transmembrane helices that al-
tered the inserted position and stability of the helices in the mem-
brane [50–54].
Energy transfer experiments (Fig. 7) clearly demonstrated that
only the wild type S5 but not its mutant could self-assemble in PC/PG
lipid vesicles. This observation indicates that the substitution of the
highly conserved glycine at 269 position with serine abrogated the
self-assembly of S5 peptide deﬁning a probable structural basis for its
malfunctioning. Furthermore, these results were supported by the
binding experiment data, which suggested that only the wild type S5
peptide formed large aggregates in negatively charged PC/PG vesicles
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alamethicin [22,45]. Signiﬁcant change in secondary structure of S5
peptide (Fig. 6) inmembrane-mimetic detergent was also observed as
a result of replacement of glycine by serine at 269 positions. Along
with the membrane-binding and the energy transfer results, it
appeared that although S5 and G269S mutant S5 peptide bound to
the lipid vesicles, only S5 peptide could self-assemble and formed
large aggregates there. Due to G269S mutation the mutant peptide
molecules might be distributed randomly in the lipid vesicles and
were unable to self-assemble in the PC/PG lipid vesicles. A glycine to
serine substitution (G389S) in the anchor region of Yersinia adhesin A
(YadA), which is a trimeric pore-forming autotransporter adhesin of
enteric yersiniae has been reported to abrogate its autotransporter
function. The substitution of this conserved glycine by serine
completely shifted the trimeric assembly of the autotransporter into
monomer and subsequently a reduced protein expression, decreased
stability and increased degradation of YadA by the periplasmic
protease were observed [55,56].
Taken together, the results of the present study reﬂect that the
mutant peptide bound to phospholipid vesicles yet assembled weakly
in the lipid vesicles and did not induce any appreciable leakage in the
PC/PG lipid vesicles. Probably, the impairment of assembly and
function of this S5 transmembrane segment as a result of substitution
of glycine to serinemay inﬂuence the activity of the KvLQT1 and could
be a possible way of how the proper functioning of the channel is
affected by this substitution.
Peptide-induced pore-formation has been frequently detected by
peptide-induced calcein release from the calcein-entrapped lipid
vesicles [24,34,57–60]. The release of calcein from calcein-entrapped
lipid vesicles in the presence of pardaxin, [24,57], melittin [58] and
alamethicin [61] has been implicated to the pore-forming activity of
the peptides. This is in contrast to the study of Benachir and Laﬂeur
[62] which suggested that calcein release induced by melittin from
calcein-entrapped 1-palmitoyl-2-oleoylphosphatidylcholine (POPC)
vesicles was due to co-operative membrane perturbation rather than
formation of pores. Similarly, magainin was proposed to permeabilize
POPC lipid vesicles as evidenced by peptide-induced calcein release
by perturbing the lipid bilayer without forming pores [63]. However,
in the present study the S5 peptide self-assembled, inserted into the
negatively charged lipid vesicles and also induced the release of
calcein from these vesicles. These properties of S5 peptidematchwith
the properties of other pore-forming peptides. Moreover, it is to be
mentioned that while studying magainin–POPC membrane interac-
tion, no aggregation or insertion of the peptide was observed [63].
Thus it is more likely that wild type S5 peptide-induced calcein
release from calcein-entrapped PC/PG lipid vesicles was associated
with pore-formation therein and G269S mutation impaired this
activity.
Literature indicates that a glycine can modulate assembly of TM
segments and is a common amino acid in the packing interface of TM
helices [64]. It is also a key amino acid in van der Waals mediated
packing of TM helices as its small size allows close interaction of TM
segments. Glycine or an apolar to polar amino acid mutation could
give rise to non-native to H-bond induced misfolding of a protein or
alteration of helical packing through steric hindrance [65]. Indeed,
eighty or so membrane proteins listed in the database of protein
misfolding associated human diseases; approximately 50% of these
contain apolar to polar amino acid substitutions in a TM helix. A
number of glycine to serine amino acid substitutions in channel
proteins have been reported that are involved with diseases. A
missense mutation in KCNQ4, G285S is reported to be involved in
dominant deafness [66]. A single-nucleotide-polymorphism (SNP) in
the KCNE1 gene leading to glycine substitution for serine at amino
acid position, 38, has been reported to be associated with increased
atrial ﬁbrillation incidence [67–70]. A G156S mutation in highly
conserved G156 of an inward rectifying K+ channel GIRK2, results inweaver phenotype that is inherited as an autosomal recessive
disorder and results in severe ataxia and cell loss in substantia nigra
[71].
Structural studies on membrane proteins are often difﬁcult due to
their high hydrophobicity, tendency to aggregate and problems in
purifying in their native states. Consequently, several studies have
been carried out recently with the synthetic peptides derived from the
potentially crucial structural and functional segments of these
membrane proteins [72–75]. It has been demonstrated that these
peptides can assume functional assembly like their parent membrane
proteins even in detergent micelles [75]. These studies have led to
important conclusions related to the structural and functional
contributions of the selected segments to the whole proteins and
also provided valuable idea about the structure of the concerned
proteins. The studies on synthetic peptides from CFTR channel [76,77],
divalent metal ion transporter [72], sodium pump γ subunit [78]
showed the effect of disease causing point mutation in the structure
and assembly of these peptides and have been proposed to contribute
in these diseases in vivo. Disease causing mutations at conserved
glycine in the peptides derived from the gamma subunit of Na, K-
ATPase and TM domain of Myelin protein zero, have been reported to
abrogate their insertion and oligomerization in model membranes
[78,79]. The present study on the effect of substitution of conserved
glycine at 269 position by serine in a S5 peptide of KvLQT1 channel
showed a signiﬁcant loss of its secondary structure in membrane-
mimetic environment, assembly and insertion property in model
membrane. Thus this mutation in the S5 segment may interfere with
the proper folding of the protein and impair its trafﬁcking, which
further could be relevant to the pathogenesis of LQT1 syndrome.
However, how exactly the G269S mutation in KvLQT1 channel causes
the pathogenesis in LQT1 syndrome remains to be determined.
In conclusion, the results presented here demonstrated the
structural and functional changes in the selected 22-residue segment
of KvLQT1 channel that occurred as a result of substitution of glycine
at 269 position by serine, involved with LQT syndrome in human.
G269S mutation produced alterations not only in afﬁnity and stability
but also in assembly of S5 peptide in the lipid vesicles. The studies of
synthetic S5 and its mutant peptide reﬂected the importance of G269
in its membrane-assembly and function of S5 peptide. Proper
assembly of any pore-forming or ion channel protein is an essential
criterion for its functional activity. Therefore, in the context of
structural and functional changes observed in the S5 segment as a
result of G269S amino acid substitution, it is possible that the same
amino acid substitution could affect the structural and functional
properties of KvLQT1 channel. Considering the fact that glycine to
serine substitution in several membrane–proteins is associated with
diseases, the present study also provides valuable information on
their possible structural and functional alteration as a result of this
amino acid substitution.
Acknowledgements
This work was supported by a Central Drug Research Institute
(CDRI) in house project no. MLP 0007M. RV acknowledges the receipt
of Senior Research Fellowship from CSIR, India. Dr. R. M. Srivastava
and Mr. B. K. Pandey are thankfully acknowledged for modifying Figs.
4 and 1 respectively.
References
[1] P. Delmas, D.A. Brown, Pathways modulating neural KCNQ/M (Kv7) potassium
channels, Nat. Rev. Neurosci. 6 (2005) 850–862.
[2] J. Robbins, KCNQ potassium channels: physiology, pathophysiology, and pharma-
cology, Pharmacol. Ther. 90 (2001) 1–19.
[3] A. Felipe, R. Vicente, N. Villalonga,M. Roura-Ferrer, R. Martinez-Marmol, L. Sole, J.C.
Ferreres, E. Condom, Potassium channels: new targets in cancer therapy, Cancer
Detect. Prev. 30 (2006) 375–385.
469R. Verma, J.K. Ghosh / Biochimica et Biophysica Acta 1798 (2010) 461–470[4] Q. Wang, M.E. Curran, I. Splawski, T.C. Burn, J.M. Millholland, T.J. VanRaay, J. Shen,
K.W. Timothy, G.M. Vincent, T. de Jager, P.J. Schwartz, J.A. Toubin, A.J. Moss, D.L.
Atkinson, G.M. Landes, T.D. Connors, M.T. Keating, Positional cloning of a novel
potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias, Nat.
Genet. 12 (1996) 17–23.
[5] D.M. Roden, A.L. George Jr., P.B. Bennett, Recent advances in understanding the
molecular mechanisms of the long QT syndrome, J. Cardiovasc. Electrophysiol. 6
(1995) 1023–1031.
[6] M.E. Curran, I. Splawski, K.W. Timothy, G.M. Vincent, E.D. Green, M.T. Keating, A
molecular basis for cardiac arrhythmia: HERGmutations cause long QT syndrome,
Cell 80 (1995) 795–803.
[7] M. Boutjdir, M. Restivo, Y. Wei, K. Stergiopoulos, N. el-Sherif, Early after-
depolarization formation in cardiac myocytes: analysis of phase plane patterns,
action potential, and membrane currents, J. Cardiovasc. Electrophysiol. 5 (1994)
609–620.
[8] T. Jespersen, M. Grunnet, S.P. Olesen, The KCNQ1 potassium channel: from gene to
physiological function, Physiology (Bethesda) 20 (2005) 408–416.
[9] M. Schwake, T.J. Jentsch, T. Friedrich, A carboxy-terminal domain determines the
subunit speciﬁcity of KCNQ K+ channel assembly, EMBO Rep. 4 (2003) 76–81.
[10] C.E. Chiang, D.M. Roden, The long QT syndromes: genetic basis and clinical
implications, J. Am. Coll. Cardiol. 36 (2000) 1–12.
[11] E. Herbert, M. Trusz-Gluza, E. Moric, E. Smilowska-Dzielicka, U. Mazurek, T.
Wilczok, KCNQ1 gene mutations and the respective genotype–phenotype
correlations in the long QT syndrome, Med. Sci. Monit. 8 (2002) RA240–RA248.
[12] G. Loussouarn, I. Baro, D. Escande, KCNQ1 K+ channel-mediated cardiac
channelopathies, Methods Mol. Biol. 337 (2006) 167–183.
[13] G.M. Vincent, K.W. Timothy, M. Leppert, M. Keating, The spectrum of symptoms
and QT intervals in carriers of the gene for the long-QT syndrome, N. Engl. J. Med.
327 (1992) 846–852.
[14] G.M. Vincent, Hypothesis for the molecular physiology of the Romano–Ward long
QT syndrome, J. Am. Coll. Cardiol. 20 (1992) 500–503.
[15] W. Creighton, R. Virmani, R. Kutys, A. Burke, Identiﬁcation of novel missense
mutations of cardiac ryanodine receptor gene in exercise-induced sudden death at
autopsy, J. Mol. Diagn. 8 (2006) 62–67.
[16] M.J. Ackerman, D.J. Tester, C.J. Porter, Swimming, a gene-speciﬁc arrhythmogenic
trigger for inherited long QT syndrome, Mayo Clin. Proc. 74 (1999) 1088–1094.
[17] M.J. Ackerman, D.J. Tester, C.J. Porter, W.D. Edwards, Molecular diagnosis of the
inherited long-QT syndrome in a woman who died after near-drowning, N. Engl. J.
Med. 341 (1999) 1121–1125.
[18] S. Chen, L. Zhang, R.M. Bryant, G.M. Vincent, M. Flippin, J.C. Lee, E. Brown, F.
Zimmerman, R. Rozich, P. Szafranski, C. Oberti, R. Sterba, D. Marangi, P.J. Tchou,
M.K. Chung, Q.Wang, KCNQ1mutations in patients with a family history of lethal
cardiac arrhythmias and sudden death, Clin. Genet. 63 (2003) 273–282.
[19] G.B. Fields, R.L. Noble, Solid phase peptide synthesis utilizing 9-ﬂuorenylmethox-
ycarbonyl amino acids, Int. J. Pept. Protein Res. 35 (1990) 161–214.
[20] E. Bouchayer, C.I. Stassinopoulou, C. Tzougraki, D. Marion, P. Gans, NMR and CD
conformational studies of the C-terminal 16-peptides of Pseudomonas aeruginosa
c551 and Hydrogenobacter thermophilus c552 cytochromes, J. Pept. Res. 57
(2001) 39–47.
[21] E. Kaiser, R.L. Colescott, C.D. Bossinger, P.I. Cook, Color test for detection of free
terminal amino groups in the solid-phase synthesis of peptides, Anal. Biochem. 34
(1970) 595–598.
[22] D. Rapaport, Y. Shai, Aggregation and organization of pardaxin in phospholipid
membranes. A ﬂuorescence energy transfer study, J. Biol. Chem. 267 (1992)
6502–6509.
[23] J.K. Ghosh, M. Ovadia, Y. Shai, A leucine zipper motif in the ectodomain of Sendai
virus fusion protein assembles in solution and in membranes and speciﬁcally
binds biologically-active peptides and the virus, Biochemistry 36 (1997)
15451–15462.
[24] Y. Shai, Y.R. Hadari, A. Finkels, pH-dependent pore formation properties of
pardaxin analogues, J. Biol. Chem. 266 (1991) 22346–22354.
[25] J.K. Ghosh, Y. Shai, A peptide derived from a conserved domain of Sendai virus
fusion protein inhibits virus–cell fusion. A plausible mode of action, J. Biol. Chem.
273 (1998) 7252–7259.
[26] G.R. Bartlett, Phosphorus assay in column chromatography, J. Biol. Chem. 234
(1959) 466–468.
[27] N. Greenﬁeld, G.D. Fasman, Computed circular dichroism spectra for the
evaluation of protein conformation, Biochemistry 8 (1969) 4108–4116.
[28] C.S. Wu, K. Ikeda, J.T. Yang, Ordered conformation of polypeptides and proteins in
acidic dodecyl sulfate solution, Biochemistry 20 (1981) 566–570.
[29] D. Rapaport, Y. Shai, Interaction of ﬂuorescently labeled pardaxin and its
analogues with lipid bilayers, J. Biol. Chem. 266 (1991) 23769–23775.
[30] G. Schwarz, H. Gerke, V. Rizzo, S. Stankowski, Incorporation kinetics in a
membrane, studied with the pore-forming peptide alamethicin, Biophys. J. 52
(1987) 685–692.
[31] G. Beschiaschvili, J. Seelig, Melittin binding to mixed phosphatidylglycerol/
phosphatidylcholine membranes, Biochemistry 29 (1990) 52–58.
[32] G. Beschiaschvili, J. Seelig, Peptide binding to lipid bilayers. Binding isotherms and
zeta-potential of a cyclic somatostatin analogue, Biochemistry 29 (1990)
10995–101000.
[33] S.P. Yadav, A. Ahmad, J.K. Ghosh, Addition of a small hydrophobic segment from
the head region to an amphipathic leucine zipper like motif of E. coli toxin
hemolysin E enhances the peptide-induced permeability of zwitterionic lipid
vesicles, Biochim. Biophys. Acta 1768 (2007) 1574–1582.
[34] S.P. Yadav, B. Kundu, J.K. Ghosh, Identiﬁcation and characterization of an
amphipathic leucine zipper-like motif in Escherichia coli toxin hemolysin E.Plausible role in the assembly and membrane destabilization, J. Biol. Chem. 278
(2003) 51023–51034.
[35] E. Gazit, Y. Shai, Structural characterization, membrane interaction, and speciﬁc
assembly within phospholipidmembranes of hydrophobic segments from Bacillus
thuringiensis var. israelensis cytolytic toxin, Biochemistry 32 (1993)
12363–12371.
[36] E. Gazit, Y. Shai, The assembly and organization of the alpha 5 and alpha 7 helices
from the pore-forming domain of Bacillus thuringiensis delta-endotoxin.
Relevance to a functional model, J. Biol. Chem. 270 (1995) 2571–2578.
[37] T.M. Allen, G. Cleland, Serum-induced leakage of liposome contents, Biochim.
Biophys. Acta 597 (1980) 418–426.
[38] Y. Pouny, D. Rapaport, A. Mor, P. Nicolas, Y. Shai, Interaction of antimicrobial
dermaseptin and its ﬂuorescently labeled analogues with phospholipid mem-
branes, Biochemistry 31 (1992) 12416–12423.
[39] B. Hamplova, V. Pelouch, O. Novakova, J. Skovranek, B. Hucin, F. Novak,
Phospholipid composition of myocardium in children with normoxemic and
hypoxemic congenital heart diseases, Physiol. Res. 53 (2004) 557–560.
[40] G. Rocquelin, L. Guenot, P.O. Astorg, M. David, Phospholipid content and fatty acid
composition of human heart, Lipids 24 (1989) 775–780.
[41] R.A. Kenner, A.A. Aboderin, A new ﬂuorescent probe for protein and
nucleoprotein conformation. Binding of 7-(p-methoxybenzylamino)-4-nitro-
benzoxadiazole to bovine trypsinogen and bacterial ribosomes, Biochemistry 10
(1971) 4433–4440.
[42] G. Bailin, J.R. Huang, Fluorescence properties of the Ca2+, Mg2(+)-ATPase
protein of sarcoplasmic reticulum labeled with 7-chloro-4-nitrobenzo-2-oxa-1, 3-
diazole, FEBS Lett. 259 (1990) 254–256.
[43] K. Rajarathnam, J. Hochman, M. Schindler, S. Ferguson-Miller, Synthesis, location,
and lateral mobility of ﬂuorescently labeled ubiquinone 10 in mitochondrial and
artiﬁcial membranes, Biochemistry 28 (1989) 3168–3176.
[44] A. Chattopadhyay, E. London, Parallax method for direct measurement of
membrane penetration depth utilizing ﬂuorescence quenching by spin-labeled
phospholipids, Biochemistry 26 (1987) 39–45.
[45] V. Rizzo, S. Stankowski, G. Schwarz, Alamethicin incorporation in lipid bilayers: a
thermodynamic study, Biochemistry 26 (1987) 2751–2759.
[46] E. Gazit, A. Boman, H.G. Boman, Y. Shai, Interaction of the mammalian anti-
bacterial peptide cecropin P1 with phospholipid vesicles, Biochemistry 34
(1995) 11479–11488.
[47] S.P. Yadav, A. Ahmad, B.K. Pandey, R. Verma, J.K. Ghosh, Inhibition of lytic activity
of Escherichia coli toxin hemolysin E against human red blood cells by a leucine
zipper peptide and understanding the underlying mechanism, Biochemistry 47
(2008) 2134–2142.
[48] B.K. Fung, L. Stryer, Surface density determination in membranes by ﬂuorescence
energy transfer, Biochemistry 17 (1978) 5241–5248.
[49] W. Shimizu, T. Noda, H. Takaki, N. Nagaya, K. Satomi, T. Kurita, K. Suyama, N. Aihara,
K. Sunagawa, S. Echigo, Y. Miyamoto, Y. Yoshimasa, K. Nakamura, T. Ohe, J.A.
Towbin, S.G. Priori, S. Kamakura, Diagnostic value of epinephrine test for
genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome, Heart
Rhythm 1 (2004) 276–283.
[50] C.N. Chin, G. von Heijne, Charge pair interactions in a model transmembrane helix
in the ER membrane, J. Mol. Biol. 303 (2000) 1–5.
[51] H. Borochov, M. Shinitzky, Vertical displacement of membrane proteins mediated
by changes in microviscosity, Proc. Natl. Acad. Sci. U. S. A. 73 (1976) 4526–4530.
[52] M. Monne, I. Nilsson, M. Johansson, N. Elmhed, G. von Heijne, Positively and
negatively charged residues have different effects on the position in the
membrane of a model transmembrane helix, J. Mol. Biol. 284 (1998) 1177–1183.
[53] C. Landolt-Marticorena, K.A. Williams, C.M. Deber, R.A. Reithmeier, Non-random
distribution of amino acids in the transmembrane segments of human type I single
span membrane proteins, J. Mol. Biol. 229 (1993) 602–608.
[54] G. Zhao, E. London, An amino acid “transmembrane tendency” scale that
approaches the theoretical limit to accuracy for prediction of transmembrane
helices: relationship to biological hydrophobicity, Protein Sci. 15 (2006)
1987–2001.
[55] U. Grosskinsky, M. Schutz, M. Fritz, Y. Schmid, M.C. Lamparter, P. Szczesny, A.N.
Lupas, I.B. Autenrieth, D. Linke, A conserved glycine residue of trimeric
autotransporter domains plays a key role in Yersinia adhesin A autotransport,
J. Bacteriol. 189 (2007) 9011–9019.
[56] E. Hoiczyk, A. Roggenkamp, M. Reichenbecher, A. Lupas, J. Heesemann, Structure
and sequence analysis of Yersinia YadA and Moraxella UspAs reveal a novel class
of adhesins, EMBO J. 19 (2000) 5989–5999.
[57] Doron Rapaport, Ruth Peled, Shlomo Nir, Yechiel Shai, Reversible surface
aggregation in pore formation by pardaxin, Biophys. J. 70 (1996) 2502–2512.
[58] Katsumi Matsuzaki, Shuji Yoneyama, Koichira Miyajima, Pore formation and
translocation of melittin, Biophys. J. 73 (1997) 831–838.
[59] S. Kobayashi, Y. Hirakura, Katsumi Matsuzaki, Bacteria-selective synergism
between the antimicrobial peptides alpha-helical magainin 2 and cyclic beta-
sheet tachyplesin I: toward cocktail therapy, Biochemistry 40 (2001)
14330–14335.
[60] Takashi Katsu, Tomonori Imamura, Keiko Komagoe, Kazufumi Masuda, Tohru
Mizushima, Simultaneous measurements of K+ and calcein release from
liposomes and the determination of pore size formed in a membrane, Anal. Sci.
23 (2007) 517–522.
[61] S.H. Portlock, M.J. Clague, R.J. Cherry, Leakage of internal markers from
eryhthrocytes and lipid vesicles included by melittin, gramicidinS and alamethi-
cin, a comparative study, Biochim. Biophys. Acta 1030 (1990) 1–10.
[62] Toni Benachir, Michel Laﬂeur, Study of vesicle leakage induced by melittin,
Biochim. Biophys. Acta 1235 (1995) 452–460.
470 R. Verma, J.K. Ghosh / Biochimica et Biophysica Acta 1798 (2010) 461–470[63] Torsten Wieprecht, Michael Beyermann, Joachim Seelig, Binding of antimicrobial
magainin peptides to electrically neutral membranes: thermodynamics and
structure, Biochemistry 38 (1999) 10377–10387.
[64] W.P. Russ, D.M. Engelman, The GxxxG motif: a framework for transmembrane
helix–helix association, J. Mol. Biol. 296 (2000) 911–919.
[65] A.W. Partridge, A.G. Therien, C.M. Deber, Polar mutations inmembrane proteins as
a biophysical basis for disease, Biopolymers 66 (2002) 350–358.
[66] C. Kubisch, B.C. Schroeder, T. Friedrich, B. Lutjohann, A. El-Amraoui, S. Marlin, C.
Petit, T.J. Jentsch, KCNQ4, a novel potassium channel expressed in sensory outer
hair cells, is mutated in dominant deafness, Cell 96 (1999) 437–446.
[67] M.C. Sanguinetti, M.E. Curran, A. Zou, J. Shen, P.S. Spector, D.L. Atkinson, M.T.
Keating, Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks)
potassium channel, Nature 384 (1996) 80–83.
[68] J. Barhanin, F. Lesage, E. Guillemare, M. Fink, M. Lazdunski, G. Romey, K(V)LQT1
and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current,
Nature 384 (1996) 78–80.
[69] L.P. Lai, C.L. Deng, A.J. Moss, R.S. Kass, C.S. Liang, Polymorphism of the gene
encoding a human minimal potassium ion channel (minK), Gene 151 (1994)
339–340.
[70] L.P. Lai, M.J. Su, H.M. Yeh, J.L. Lin, F.T. Chiang, J.J. Hwang, K.L. Hsu, C.D. Tseng, W.P.
Lien, Y.Z. Tseng, S.K. Huang, Association of the human minK gene 38G allele with
atrial ﬁbrillation: evidence of possible genetic control on the pathogenesis of atrial
ﬁbrillation, Am. Heart J. 144 (2002) 485–490.
[71] N. Patil, D.R. Cox, D. Bhat, M. Faham, R.M. Myers, A.S. Peterson, A potassium
channel mutation in weaver mice implicates membrane excitability in granule cell
differentiation, Nat. Genet. 11 (1995) 126–129.[72] Fei Li,Hongyan Li, LihongHu,MiufanKwan, GuanhuaChen,Qing-YuHe,Hongzhe Sun,
Structure, assembly, and topology of the G185Rmutant of the fourth transmembrane
domain of divalent metal transporter, J. Am. Chem. Soc. 127 (2005) 1414–1423.
[73] S.J. Opella, F.M. Marassi, J.J. Gesell, A.P. Valente, Y. Kim, M. Oblatt-Montal, M.
Montal, Structures of the M2 channel-lining segments from nicotinic acetylcho-
line and NMDA receptors by NMR spectroscopy, Nat. Struct. Biol. (1999) 374–379.
[74] A. Schulz, K. Bruns, P. Henklein, G. Krause, M. Schubert, T. Gudermann, V. Wray, G.
Schultz, Schöneberg, Requirement of speciﬁc intrahelical interactions for
stabilizing the inactive conformation of glycoprotein hormone receptors, J. Biol.
Chem. 275 (2000) 37860–37869.
[75] K.R. MacKenzie, J.H. Prestegard, D.M. Engelman, A transmembrane helix dimer:
structure and implications, Science 276 (1997) 131–133.
[76] Michael A. Massiah, Young-Hee Ko, Peter L. Pedersen, Albert S. Mildvan, Cystic
ﬁbrosis transmembrane conductance regulator: solution structures of peptides
based on the Phe508 region, the most common site of disease-causing ¢F508
mutation, Biochemistry 38 (1999) 7453–7461.
[77] Mei Y. Choi, AnthonyW. Partridge, Craig Daniels, Kai Du, Gergely L. Lukacs, Charles
M. Deber, Destabilization of the transmembrane domain induces misfolding in a
phenotypic mutant of cystic ﬁbrosis transmembrane conductance regulator,
J. Biol. Chem. 280 (2005) 4968–4974.
[78] A.G. Therien, C.M. Deber, Oligomerization of a peptide derived from the
transmembrane region of the sodium pump gamma subunit: effect of the
pathological mutation G41R, J. Mol. Biol. 322 (2002) 583–590.
[79] M.L. Plotkowski, S. Kim, M.L. Phillips, A.W. Partridge, C.M. Deber, J.U. Bowie,
Transmembrane domain of myelin protein zero can form dimers: possible
implications for myelin construction, Biochemistry 46 (2007) 12164–12173.
